Executive Director, Global Scientific Communications

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified

Salary

$265K-$331K not verified - source not recorded; timestamp not recorded

401(k) match

Not verified

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$93,011 U.S. median for this role

Projected growth (BLS Employment Projections)

+5.1% - Faster than average

220% above the BLS role benchmark for marketing aggregate.

Posted salary is far from this role benchmark; treat it as low confidence.

Matched to SOC 13-1161 - Marketing aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Schedule

Shift type

Not verified

Weekend work

Not verified

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Executive Director, Global Scientific Communications Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As a new member of the Revolution Medicines team, the Executive Director, Global Scientific Communications will lead the development and execution of a comprehensive scientific communications strategy and team, ensuring alignment across internal and external stakeholders in preparation for the company's first commercial launch in pancreatic cancer and the progression of additional pipeline assets in NSCLC, colorectal cancer, and other solid tumors. Reporting into the SVP, Global Medical Affairs, this role will will be responsible for leading our scientific communications platforms and publication strategies and contribute to medical content supporting the organization's medical and scientific engagement efforts. Key responsibilities include: Publications Strategy & Execution - Lead the development and execution of the global publication plans, ensuring alignment with clinical and scientific objectives. - Oversee and provide strategic direction for medical writing, publication planning meetings, the submission process, and timely/high-quality scientific communications and

Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.